Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Fairness in Orphan Drug Exclusivity Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Drug Pricing and Orphan Drug Act. Accelerated Approval Pathway. Orphan Drug Tax Credit. H.R.1629 - Fairness in Orphan Drug Exclusivity Act. Cures 2.0.
Inflation Reduction Act of 2022
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2021 · fourth_quarter · Q4
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act.
Orphan Drug Tax Credit Issues.
Source: Senate LDA
Rare disease initiatives. Newborn screening. Affordable Care Act (ACA) issues and enhancements as it relates to H.R.5376 - Build Back Better Act. Paid Medical and Family Leave as it relates to H.R.5376 - Build Back Better Act. Cares 2.0.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Newborn screening. Genetic testing. Health equity. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. Drug Pricing and Orphan Drug Act. COVID-19 Related Issues. Medical Nutrition.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Clinical trials. Newborn screening. User Fee Negotiations. Value Based Purchasing. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. COVID-19 Related Issues.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Newborn screening. Genetic testing. Health equity. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. Drug Pricing and Orphan Drug Act. COVID-19 Related Issues. Medical Nutrition.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Clinical trials. Newborn screening. User Fee Negotiations. Value Based Purchasing. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. COVID-19 Related Issues.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Notice of Benefit Payment Parameters. Surprise Medical Billing. Pre-Existing Conditions. User Fee Negotiations. Physician Fee Schedule. Value Based Purchasing. Integrated Review Panel. Regulation and Guidance Reform. Affordable Care Act. COVID-19 Related Issues.
Safe Step Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Health issues impacting patients with rare diseases. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Notice of Benefit Payment Parameters. Surprise Medical Billing. Pre-Existing Conditions. User Fee Negotiations. Physician Fee Schedule. Value Based Purchasing. Integrated Review Panel. Regulation and Guidance Reform. Affordable Care Act. COVID-19 Related Issues.
Rare disease initiatives. Newborn screening. Affordable Care Act (ACA) issues and enhancements as it relates to H.R.5376 - Build Back Better Act. Paid Medical and Family Leave as it relates to H.R.5376 - Build Back Better Act. Cares 2.0.
Public Health Agency Appropriations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2021 · third_quarter · Q3
Public Health Agency Appropriations.
Pharmaceutical issues impacting patients with rare diseases. Drug Pricing and Orphan Drug Act. Accelerated Approval Pathway. Orphan Drug Tax Credit. H.R.1629 - Fairness in Orphan Drug Exclusivity Act. Cures 2.0.
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. User Fee Negotiations. Newborn screening. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. COVID-19 Related Issues. Medical Nutrition. Paid Medical and Family Leave
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2021 · second_quarter · Q2
Public Health Agency Appropriations.
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Newborn screening. Genetic testing. Health equity. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. Drug Pricing and Orphan Drug Act. COVID-19 Related Issues. Medical Nutrition.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2021 · first_quarter · Q1
Health issues impacting patients with rare diseases. Rare disease initiatives. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Clinical trials. Newborn screening. User Fee Negotiations. Value Based Purchasing. Affordable Care Act (ACA) issues. Affordable Care Act (ACA) enhancements. COVID-19 Related Issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2020 · fourth_quarter · Q4
Health issues impacting patients with rare diseases. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Notice of Benefit Payment Parameters. Surprise Medical Billing. Pre-Existing Conditions. User Fee Negotiations. Physician Fee Schedule. Value Based Purchasing. Integrated Review Panel. Regulation and Guidance Reform. Affordable Care Act. COVID-19 Related Issues.
Pharmaceutical issues impacting patients with rare diseases. Prescription Drug Pricing. NBPP Proposed Rule. Biosimilar User Fee Act (BsUFA). Prescription Drug User Fee Act (PDUFA).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE